February 19, 2025 Kigali, Rwanda and San Francisco, USA

The 2nd Vaccine and Other Health Product Manufacturing Forum marked a pivotal moment for Africa’s biopharmaceutical industry with the African CDC unveiling its groundbreaking initiative—the Regional Capability and Capacity Networks (RCCNs). This initiative is a testament to the continent’s commitment to strengthening its workforce, advancing capabilities in vaccine and biomanufacturing, and enhancing the continent’s health security and self-sufficiency.

Bio Usawa Inc. applauds this strategic effort and fully supports its mission to train and mentor young professionals, fostering the expertise needed for sustainable, high-quality vaccine and biologics production. As a company dedicated to expanding access to monoclonal antibodies in Africa, we recognize that a skilled workforce is essential for driving innovation and ensuring quality manufacturing.

Bio Usawa’s Commitment to RCCNs

Leveraging our industry-leading expertise in biologics R&D, regulatory compliance, and large-scale manufacturing, Bio Usawa is ready to support RCCNs through:

• Technical Mentorship & Training – Equipping professionals with advanced biomanufacturing skills.
• Regulatory & Quality Systems Strengthening – Assisting African manufacturers in meeting global standards.
• Collaborative Research & Innovation – Partnering with key stakeholders to advance Africa’s leadership in biomanufacturing.

A Call for Collective Action

Achieving self-reliance in vaccine and biologics production requires joint efforts from governments, industry, academia, and development partners. We encourage stakeholders to collaborate with African CDC in shaping Africa’s biopharmaceutical future.

We commend African CDC for this visionary initiative and look forward to contributing our expertise to build a resilient, highly skilled biomanufacturing workforce in Africa.

About Bio Usawa, Inc. (BUI)

Bio Usawa has a singular mission: to manufacture high-quality, effective and affordable biosimilars for patients in Africa. We are applying our 100+ years of combined experience in the industry in partnership with governments, agencies, educators and health professionals to make transformative biomedicines in Africa, by Africans, for Africans and beyond. 

Click here to learn more about our company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.